Posters/Publications

Title
Venue
Type
Date

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN

Keystone Symposium on Organ Crosstalk in Obesity and NAFLD

poster

01/2018
First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640

AACR Annual Meeting

oral

04/2017
Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH

EASL International Liver Congress

poster

04/2017